{
    "clinical_study": {
        "@rank": "100669", 
        "acronym": "SUPPORT", 
        "arm_group": [
            {
                "arm_group_label": "ECA: Ethyl-2-cyanoacrate", 
                "arm_group_type": "Experimental", 
                "description": "Application of ethyl-2-cyanoacrylate (ECA) for painful cetuximab-induced rhagades"
            }, 
            {
                "arm_group_label": "Standard treatment of the institution", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard treatment of the institution to treat painful cetuximab-induced rhagades"
            }
        ], 
        "brief_summary": {
            "textblock": "The SUPPORT trial is an open-label, prospective, randomized, national multicenter\n      intervention study to evaluate the effectiveness of ethyl-2-cyanoacrylate versus the\n      standard treatment of each institution on the pain intensity and QoL in patients with\n      locally advanced head and neck cancer suffering from painful cetuximab-induced rhagades\n      during radioimmunotherapy."
        }, 
        "brief_title": "Effects of ECA on Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pain", 
        "condition_browse": {
            "mesh_term": [
                "Head and Neck Neoplasms", 
                "Stress, Psychological"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Locally advanced squamous cell carcinoma of the head and neck and participation in\n             the HICARE-phase-IV-trial\n\n          -  Cetuximab-induced painful rhagades, i.e. SUPO Score 2-3 (see Figure 2)\n\n          -  Compliance to the photo documentation\n\n          -  Ability of subject to understand character and individual consequences of the\n             clinical trial\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Cetuximab-induced rhagades without any pain, i.e. SUPO Score 1\n\n          -  Cetuximab-induced rhagades, SUPO Score 4, i.e. superinfection of the rhagades\n\n          -  Patients not being enrolled in the HICARE trial\n\n          -  Substance misuse, psychoactive substance abuse or psychological/social conditions\n             leading to a decreased patients' compliance with possible bad influence to the\n             results of the study\n\n          -  Known allergic reaction to ethyl-2-cyanoacrylate (ECA)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01693159", 
            "org_study_id": "Uni-HD-2010-33-40-1003"
        }, 
        "intervention": [
            {
                "arm_group_label": "ECA: Ethyl-2-cyanoacrate", 
                "description": "In the experimental arm patients will be topically treated with the liquid glue ethyl-2-cyanoacrylate (ECA).", 
                "intervention_name": "ECA", 
                "intervention_type": "Device", 
                "other_name": "Ethyl-2-cyanoacrylate (ECA)"
            }, 
            {
                "arm_group_label": "Standard treatment of the institution", 
                "description": "Standard treatment of the institution to treat painful cetuximab-induced rhagades", 
                "intervention_name": "Standard topical treatment of the institution, e.g. Lotio", 
                "intervention_type": "Other", 
                "other_name": "Ointment, Creme, Lotio, for example dexpanthenol-containing topical treatment"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ethyl 2-cyanoacrylate", 
                "Cetuximab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Painful cetuximab-induced rhagades", 
            "Radioimmunotherapy", 
            "Head and neck cancer"
        ], 
        "lastchanged_date": "August 26, 2013", 
        "location": {
            "contact": {
                "email": "karin.potthoff@med.uni-heidelberg.de", 
                "last_name": "Karin Potthoff, MD", 
                "phone": "+496221568201"
            }, 
            "contact_backup": {
                "email": "gregor.habl@med.uni-heidelberg.de", 
                "last_name": "Gregor Habl, MD", 
                "phone": "+496221568201"
            }, 
            "facility": {
                "address": {
                    "city": "Heidelberg", 
                    "country": "Germany", 
                    "zip": "69120"
                }, 
                "name": "University of Heidelberg Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Karin Potthoff, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Gregor Habl, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Matthias Haefner, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Juergen Debus, Prof. Dr. Dr.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Controlled Multicenter Trial to Evaluate the Effects of Ethyl-2-cyanoacrylate on Pain Intensity and Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades During Radioimmunotherapy", 
        "other_outcome": [
            {
                "description": "SUPO-Score for classification of cetuximab-induced rhagades:\nGrade 1:  Rhagades without clinical symptoms\nGrade 2:  Painful rhagades Grade 2a:   Moderate pain, no impairment of activity in the daily routine (ADL) Grade 2b:   Severe pain and impairment of the activities of daily living (ADL) Grade 3:  Painful, deep and spontaneously bleeding rhagades\nGrade 4:  Superinfection of the rhagades (detection of bacterial growth) Grade 4a: Local infection Grade 4b: Systemic infection\nGrade 5:  Death due to complications of the rhagades", 
                "measure": "SUPO-Score for classification of cetuximab-induced rhagades", 
                "safety_issue": "No", 
                "time_frame": "24 hours and 5 to 7 days after application of treatment"
            }, 
            {
                "description": "Adverse Events of ECA due to NCI CTCAE v. 4.02", 
                "measure": "Adverse Events of ECA", 
                "safety_issue": "Yes", 
                "time_frame": "from time of randomization untio end of study, i.e. until 5 to 7 days after application of treatment"
            }
        ], 
        "overall_contact": {
            "email": "karin.potthoff@med.uni-heidelberg.de", 
            "last_name": "Karin Potthoff, Dr.", 
            "phone": "+496221568201"
        }, 
        "overall_contact_backup": {
            "email": "martin.indorf@iomedico.com", 
            "last_name": "Martin Indorf, Dr.", 
            "phone": "+497611524257"
        }, 
        "overall_official": {
            "affiliation": "National Center for Tumor Diseases, Heidelberg", 
            "last_name": "Karin Potthoff, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "pain intensity quantified by the visual analogue scale (VAS)", 
            "measure": "pain intensity 24 hours after application of ECA or the standard treatment quantified by the visual analogue scale (VAS)", 
            "safety_issue": "No", 
            "time_frame": "24 hours after application"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01693159"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Evaluation of QoL assessed by the EORTC-QoL-C30 questionnaire and the Dermatological Life Quality Index (DLQI)", 
            "measure": "Evaluation of QoL", 
            "safety_issue": "No", 
            "time_frame": "5 to 7 days after application of treatment"
        }, 
        "source": "National Center for Tumor Diseases, Heidelberg", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Heidelberg University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "iOMEDICO AG", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "National Center for Tumor Diseases, Heidelberg", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}